GE Healthcare, based in Waukesha, Wis., has entered into a strategic, long-term partnership with Roche, based in Basel, Switzerland, to develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. The partnership seeks to allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring, and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.
For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate, and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic, and sequencing data, helping physicians to identify, or even predict, severe complications before they strike.
“This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree,” says Kieran Murphy, president and CEO of GE Healthcare. “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”
“This unique partnership will deliver innovative solutions and insights in clinical decision-making,” says Roland Diggelmann, CEO of Roche Diagnostics. “Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”
